Trial Profile
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Registrational; Therapeutic Use
- Sponsors Ikaria Holdings; INO Therapeutics; Mallinckrodt Inc.
- 10 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 May 2014 New trial record
- 16 Mar 2012